Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer

Tyme Technologies (NASDAQ:TYME) announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the Company’s Phase II trial in metastatic pancreatic cancer ahead of the trial’s anticipated timeline.

As quoted in the press release:

“Our enrollment targets are meaningfully ahead of expectations due to a mix of some top research centers driving repeated enrollment and many sites getting their first subject into the trial shortly after they opened for participation,” said Dr. Giuseppe Del Priore, Tyme’s Chief Medical Officer.  “We have seen a high level of both physician and patient excitement, with exemplary sites such as Virginia Mason, Washington University St. Louis, City of Hope, University of Rochester and Sarcoma Oncology in Santa Monica leading accrual.”

Dr. Vincent Picozzi, Director of the Pancreas Center of Excellence at Virginia Mason Medical Center in Seattle and a principle investigator for the trial stated, “This protocol has generated more interest and excitement among patients with pancreatic cancer than any I have ever seen.”

Click here to read the full press release.